DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of a Proton Pump Inhibitor on GleevecĀ® in Healthy Volunteers

Information source: University of Pittsburgh
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: Imatinib Mesylate (Drug); Omeprazole (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Pittsburgh

Official(s) and/or principal investigator(s):
Jan H. Beumer, PharmD, PhD, Principal Investigator, Affiliation: University of Pittsburgh


This is a research study that will investigate the effects of proton pump inhibitors (often used to treat stomach upset) on Gleevec® (a drug that is FDA-approved to treat some types of cancer) in healthy volunteers. Twelve healthy volunteers (six men and six women) will be recruited to complete the study. This research study will compare Gleevec® in the body when taken with and without proton pump inhibitors (PPI). Each volunteer will receive a 400 mg pill of Gleevec® on two occasions. On one occasion they will take the dose of GleevecĀ® alone (without PPI). On another occasion, they will take the GleevecĀ® after taking 40 mg of PPI daily by mouth for six days. Several blood samples will be drawn to measure the concentrations of GleevecĀ® and its breakdown products in the blood, with and without the influence of PPI.

Clinical Details

Official title: Effect of a Proton Pump Inhibitor (Omeprazole, Prilosec®) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS258)

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To define the effect of omeprazole administration on the pharmacokinetics (in particular the area under the GleevecĀ® plasma concentration versus time curve) of GleevecĀ® in healthy volunteers.

Detailed description: This is an open-label, single-institution, randomized cross-over, fixed schedule study of the effects of proton pump inhibitors (PPI) on Imatinib Mesylate (GleevecĀ®) pharmacokinetics. Healthy volunteers will be recruited to participate in this study such that twelve subjects (6 men / 6 women) will complete the study. GleevecĀ® pharmacokinetics will be assessed after oral administration of GleevecĀ® and after oral administration of GleevecĀ® with concomitant administration of PPI (PrilosecĀ® Delayed-Release Capsules). GleevecĀ® will be administered at a dose of 400 mg, and the PPI (PrilosecĀ®) at a dose level of 40 mg daily for 6 consecutive days. Half of the subjects will receive PrilosecĀ® starting 5 days before Day 1 through Day 1 along with GleevecĀ® on Day 1, and GleevecĀ® alone on Day 15. The other half will receive PrilosecĀ® on Days 10-15, along with GleevecĀ® on Day 15, and GleevecĀ® alone on Day 1. On days that both drugs are administered, the PrilosecĀ® will be administered 15 minutes before the GleevecĀ® dose.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Healthy men or women 18 years of age or older. Healthy subjects are defined as

individuals who are free from clinically significant illness or disease (such as coronary arterial disease, chronic heart failure, bleeding disorder, hypertension, chronic renal failure etc.) as determined by their medical history, physical examination, and laboratory studies.

- Body Mass Index (BMI) < 31 kg/m^2 (weight/height^2).

- Female subjects of childbearing potential must have negative pregnancy test within 7

days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.

- Written, voluntary informed consent.

- Subjects participating in the protocol entitled "IRB: 0701014: Effect of Antacids

(Mg-Al-based) on Imatinib Mesylate (GleevecĀ®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257) (UPCI #06-088)" will be eligible for participation in this study provided they meet all other eligibility criteria for this study. Exclusion Criteria:

- Abnormal marrow function as defined by leucocyte, neutrophil, or platelet counts

outside of normal limits.

- Any evidence of renal dysfunction (proteinuria; serum creatinine > upper limit of

normal; or if serum creatinine > upper limit of normal, a calculated creatinine clearance < 60 mL/min/1. 73 m2).

- Impaired hepatic function (liver enzymes greater than the upper limit of normal or

bilirubin outside the normal range).

- Taking any medications (including over the counter products), herbal products,

mineral supplements or vitamins (other than a daily multivitamin preparation), other than contraceptives (for women), within 2 weeks of start of the study. All forms of contraceptive medication are permissible for this study and would not result in a female's exclusion from participation. Patients who take medications on a chronic basis, such as antihypertensive medications or thyroid replacement therapy, etc. are not eligible for the study.

- Subjects that have received any other investigational agents within 28 days of first

day of study drug dosing.

- Female subjects who are pregnant or breast-feeding.

Locations and Contacts

University of Pittsburgh Cancer Institute / Clinical and Translational Research Center (Hillman Cancer Center and Montefiore University Hospital locations), Pittsburgh, Pennsylvania 15232 / 15213, United States
Additional Information

Starting date: April 2007
Last updated: December 2, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017